X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ISA101b (cemiplimab) is a PD-1 inhibitor vaccine drug candidate, which is currently being evaluated for the treatment of patients with advanced HPV16-positive oropharyngeal cancer.
Lead Product(s): ISA101b,Cemiplimab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
ISA104 is designed to developed using Synthetic Long Peptide (SLP®) technology and create a strong and specific immune response against HBV, with the aim to functionally cure chronically infected patients.
Lead Product(s): ISA104
Therapeutic Area: Infections and Infectious Diseases Product Name: ISA104
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers. It plays a crucial role in tumor survival and spread.
Lead Product(s): ISA103,Undisclosed
Therapeutic Area: Oncology Product Name: ISA103
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Cancer Focus Fund
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 04, 2023
Details:
ISA101b immunotherapy targets human papillomavirus type 16 (HPV16) positive cancers. It induces strong and specific immune responses to the HPV16 virus, and (re-)establishes a powerful and targeted T-cell immune response against infected and/or cancerous cells and tissues.
Lead Product(s): ISA101b,Cemiplimab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
ISA101b, consists of 12 synthetic long peptide derived from oncogenic protein of HPV 16 virus in combination with nivolumab in cancer demonstrated deep and durable responses have a positive effect on patient prognosis with patients disease-free for more than 44 months.
Lead Product(s): ISA101b,Nivolumab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
In a new phase 2 study, ISA101b induces strong and specific immune responses to HPV16 virus proteins, and (re-)establishes a powerful T-cell immune response against virus infected and/or cancerous cells and tissues.
Lead Product(s): ISA101b,Cemiplimab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
Libtayo is an anti-PD-1 antibody that is being jointly developed by Regeneron and Sanofi. The phase 2 study enrols patients with advanced HPV16 positive oropharyngeal head and neck cancer that failed previous anti-PD1 treatment.
Lead Product(s): ISA101b,Cemiplimab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
ISA104 is an immunotherapy based on ISA's Synthetic Long Peptide (SLP®) technology designed to direct a strong and specific immune response against the hepatitis B virus (HBV), with the aim to cure chronically infected patients.
Lead Product(s): ISA104
Therapeutic Area: Infections and Infectious Diseases Product Name: ISA104
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Health~Holland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 20, 2021
Details:
ISA106 is an immunotherapy agent that is intended to treat patients with SARS-CoV2 infections, and prevent progressive pneumonia and further complications – thereby avoiding admission to hospital and ICU.
Lead Product(s): ISA106
Therapeutic Area: Infections and Infectious Diseases Product Name: ISA106
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
The study in previously untreated patients with intermediate-risk head and neck cancer associated with human papilloma virus subtype 16 (HPV-16) will evaluate the efficacy of ISA101b and pembrolizumab (Keytruda®) in combination with cisplatin and radiotherapy.
Lead Product(s): ISA101b,Pembrolizumab
Therapeutic Area: Oncology Product Name: ISA101b
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: UPMC Hillman Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
